Add listing
    0
    Add listing

    Medicxi: New EUR 400m fund to power next wave of biopharma entrepreneurs and drug hunters

    • Tuesday, July 23, 2019 @ 12:00 am
    • EUR 400 million Medicxi III fund, closed in just six weeks, and brings the total funds raised by Medicxi in the last three years to over UDD 1 billion
    • Medicxi III will invest across the full healthcare continuum, from discovery to late stage clinical assets, empowering ambitious scientific entrepreneurs and drug hunters
    • Novartis and Johnson & Johnson Innovation - JJDC, Inc. are returning cornerstone investors, with new investors including established hospital foundations and medical institutions

    Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new EUR 400 million fund. This brings the total amount raised by Medicxi in the last three years to over USD 1 billion.

     

    From this single fund, Medicxi will invest in early and late stage biopharma companies across the full healthcare continuum from discovery to late stage clinical assets. Cornerstone strategic investors in Medicxi III are Novartis and Johnson & Johnson Innovation - JJDC, Inc. (JJDC), both of whom have backed Medicxi in earlier funds. The fund also includes all of the institutional limited partners that previously invested in Medicxi's funds, as well as several new investors, including established hospital foundations and medical institutions.

     

    Medicxi III will be supported by the Medicxi Scientific Advisory Board, which benefits from the scientific and commercial expertise of senior executives from Novartis, the Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline and Verily (an Alphabet company).

     

    The new fund will continue to focus on Medicxi's pioneering 'asset-centric' investment model as well as investing in fully integrated private companies with an underlying platform and/or a pipeline of assets that Medicxi believes can deliver licensed pharmaceutical products to satisfy unmet medical needs.

     

    The size of the fund and the speed with which it was closed reflects the continued maturity of the life sciences sector across Europe, with investors now prioritizing their attention and support for emerging biopharma companies and their efforts to translate breakthrough science into pipelines of new drugs.

     

    Francesco De Rubertis, co-founder and Partner at Medicxi, said: "Medicxi III is one of the largest biotech funds in Europe and consolidates Medicxi's position as a key operating platform for scientific entrepreneurs and drug hunters. We are grateful to our LPs who made it possible to get the fund closed within only a few weeks."

    You may also be interested in